EQS Group-News: Zur Rose Group AG / Key word(s): AGMEGM
Zur Rose Group AG publishes invitation to the Annual General Meeting on 29 April 2021
Zur Rose Group AG today has published the invitation to the Annual General Meeting on 29 April 2021. As a result of the extraordinary situation related to the Covid-19 pandemic, also at this year's Annual General Meeting the personal attendance of shareholders on site will not be possible. Shareholders may only be represented by the independent proxy. In a short video interview, the Chairman of the Board of Directors Prof. Stefan Feuerstein and CEO Walter Oberhänsli are addressing the shareholders personally. They look back on the past financial year and discuss current strategic initiatives. The video is available at www.zurrosegroup.com, "Investors & Media", "General Meeting of Shareholders".
Proposal for creation of authorized capital and increase of the conditional capital
With the requested capital increases, the Board of Directors wants to maintain the financial flexibility of Zur Rose Group AG. By proposing the simultaneous creation of authorized capital and increase of the conditional capital, the Board of Directors wishes also to ensure that it has the flexibility to use the appropriate financing instrument in each case. The proposed capital of a total of 10 percent of the registered share capital is in line with comparable companies.
Proposal for the election of Prof. Dr. Andréa Belliger as member of the Board of Directors
In order to take appropriate account of gender diversity, the Board of Directors has set itself the goal of having each gender represented on the Board of Directors by at least 30 percent from 2023 onwards at the latest.
The invitation to the Annual General Meeting of Zur Rose Group AG with the full agenda is available at www.zurrosegroup.com | Investors & Media | General Meeting or at the following link: https://www.zurrosegroup.com/websites/zurrosegroup/English/2070/general-meeting-of-shareholders.html. The voting results will be published by press release shortly after the Annual General Meeting.
Investors and analyst contact
20 April 2021 First Quarter Trading Update
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain and France. Now serving 10.5 million active customers in core European markets, Zur Rose generated revenue of CHF 1,752 million (including Medpex and Apotal) in 2020.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1181355|
|End of News||EQS Group News Service|